secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001558370-24-006200
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M
--------------------------------------------------------------------------------

- Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.
- Reaffirmed FY 2024 net revenue guidance of $700-720M.
- Pipeline: sNDA for pitolisant in IH planned H2 2024; pediatric narcolepsy PDUFA June 21, 2024.
- Licensed TPM-1116 (orexin-2 agonist) for narcolepsy; IND expected mid-2025.
- Acquired Epygenix for rare epilepsy; clemizole Dravet/LGS pivotal trial topline 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/0001558370-24-006200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/hrmy-20240430x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer